ADC Therapeutics SA reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 14.49 million compared to USD 76.32 million a year ago. Net loss was USD 47.81 million compared to USD 50.61 million a year ago. Basic loss per share from continuing operations was USD 0.58 compared to USD 0.65 a year ago.
For the nine months, revenue was USD 52.77 million compared to USD 140.11 million a year ago. Net loss was USD 154.35 million compared to USD 131.64 million a year ago. Basic loss per share from continuing operations was USD 1.89 compared to USD 1.7 a year ago.